Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study

• Published in: Cancer medicine (Malden, MA) Vol. 10; no. 24; pp. 8866 - 8875
• Main Authors: Morgenstern, Yael, Aumann, Shlomzion, Goldschmidt, Neta, Gatt, Moshe E., Nachmias, Boaz, Horowitz, Netanel A.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.12.2021; John Wiley and Sons Inc; Wiley
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-cell lymphoma; Chemotherapy; Clinical Cancer Research; Cyclophosphamide; Cyclophosphamide - pharmacology; Cyclophosphamide - therapeutic use; DA‐EPOCH‐R; Doxorubicin; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Electronic medical records; Etoposide; Etoposide - pharmacology; Etoposide - therapeutic use; Female; Humans; Immunotherapy; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Mediastinal Neoplasms - drug therapy; Mediastinal Neoplasms - mortality; Monoclonal antibodies; Neutropenia; Patients; Prednisone; Prednisone - pharmacology; Prednisone - therapeutic use; Primary mediastinal B‐cell lymphoma (PMBCL); Radiation therapy; radiation therapy (RT); Remission (Medicine); Retrospective Studies; Rituximab; R‐CHOP/R‐ICE; Stomatitis; Survival Analysis; Tomography; Toxicity; Treatment Outcome; Vincristine; Vincristine - pharmacology; Vincristine - therapeutic use; Primary mediastinal B-cell lymphoma (PMBCL); radiation therapy (RT); R-CHOP/R-ICE; DA-EPOCH-R

Purpose Primary mediastinal B‐cell lymphoma (PMBCL) is a rare subtype of diffuse large B‐cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose‐adjusted (DA) EPOCH‐R (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubici...